Drug intelligence / Profile preview

ethylsuccinoylazolamide

Development stage: Preclinical
Modality: Small Molecules
Administration: Ophthalmic

Overview

Ethylsuccinoylazolamide is a novel bis(carbonyl)amidothiadiazole sulfonamide designed as a topically active ocular carbonic anhydrase (CA) inhibitor. It possesses specific lipid and water solubilities and pKa values that are comparable to acetazolamide, a known CA inhibitor. The drug demonstrates in vitro carbonic anhydrase inhibitory activity and has shown ocular hypotensive effects when applied topically to the corneas in animal models. Its development is aimed at managing glaucoma by reducing intraocular pressure.

Targets

CA (Carbonic anhydrase)

Beyond the preview

Go deeper on ethylsuccinoylazolamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethylsuccinoylazolamide.

Explore the full profile